ORTHOCELL LIMITED — Director's Dealing 2020

Nov 22, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited

ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

director for the purposes of section	205G of the Corporations Act.
Name of Director	Paul Anderson
Date of last notice	20/10/2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Anderson is a trustee and beneficiary of the Elwing Superannuation Fund Nicole Telford – spouse
Date of change	19/11/2020
No. of securities held prior to change Paul Anderson & Nicole Telford Paul Anderson Nicole Telford Paul Anderson & Nicole Telford Fund>	6,403,335 Ordinary Shares 16 Ordinary Shares 2,300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 4,000,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024 850,0000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 500,000 Unlisted Options exercisabe at $0.617 expiring 20 November 2022 1,200,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024 629,204 Ordinary Shares 13,692 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Unlisted Warrants
Number acquired	-
Number disposed	13,692
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change Paul Anderson and Nicole Telford Paul Anderson Nicole Telford Paul Anderson and Nicole Telford (Mr Anderson is a trustee and beneficiary of the Elwing Superannuation Fund)	6,403,335 Ordinary Shares 16 Ordinary Shares 2,300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 4,000,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024 850,0000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 500,000 Unlisted Options exercisabe at $0.617 expiring 20 November 2022 1,200,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024 629,204 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Unlisted Warrants

• See chapter 19 for defined terms.

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Part 3 Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.s

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and made be made public.

Introduced 30/09/2001

Introduced 30/09/2001
Name of entity:	Orthocell Limited
ABN:	57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

director for the purposes	of section 205G of the Corporations Act.
Name of Director:	Stewart Washer
Date of last notice:	20/10/2020

Part 1 - Change of director’s relevant interests in securities

Note: In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust. In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust) Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiary of the trust)
Date of change	19/11/2020
No. of securities held prior to change
Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust)	314,417 Ordinary Shares 417,424 Ordinary Shares 1,850,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 2,000,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024

• See chapter 19 for defined terms

Appendix 3Y pg. 1

Appendix 3Y Change of Director’s Interest Notice

	Appendix 3Y Change of Director’s Interest Notice
Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiary of the trust)	235,994 Ordinary Shares 95,842 Unlisted Warrants exercisable at $0.58 on or before 19 November 202
Class changed	Unlisted Warrants
Number acquired	-
Number disposed	95,842
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change
Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Dr Stewart James Washer & Dr Patrizia Derna Washer (Dr Washer is a trustee and beneficiary of the Trust) Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiaryof the trust)	314,417 Ordinary Shares 417,424 Ordinary Shares 1,850,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 2,000,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024 235,994 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Unlisted Warrants

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: if consideration is non-cash, provide details and an estimated valuation	N/A

• See chapter 19 for defined terms

Appendix 3Y pg. 2

Appendix 3Y Change of Director’s Interest Notice

Interest after changes N/A

Part 3 – Closed Period

Part 3 – Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms

Appendix 3Y pg. 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lars Lidgren
Date of last notice	20/10/2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Algora AB managed by Banque Carnegie Sweden (Professor Lidgren is a director of Algora AB)
Date of change	19/11/2020
No. of securities held prior to change Algora AB Sweden Managed by Banque Carnegie Sweden with securites registered as follows: JP Morgan Nominees Australia Limited Diamonex Ltd Algora AB Sweden	365,344 Ordinary Shares 768,091 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 500,000 Unlisted Options exercisable at $0.617 expiring 20 November 2022

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

	500,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024
Class	Unlisted Warrants
Number acquired	-
Number disposed	54,767
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change Algora AB Sweden Managed by Banque Carnegie Sweden with securites registered as follows: JP Morgan Nominees Australia Limited Diamonex Ltd Algora AB Sweden	365,344 Ordinary Shares 768,091 Ordinary Shares 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 500,000 Unlisted Options exercisable at $0.617 expiring 20 November 2022 500,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Unlisted Warrants

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

• See chapter 19 for defined terms.

Appendix

3Y

2

Page

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

3 Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Qi Xiao Zhou
Date of last notice	20/10/2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	19/11/2020
No. of securities held prior to change Qi Xiao Zhou	6,103,492 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021(vesting conditions set out in NOM for General Meeting held on 7 May 2018) 400,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024
Class	Unlisted Warrants
Number acquired	-
Number disposed	54,767

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation

No. of securities held after change Qi Xiao Zhou	6,103,492 Ordinary Shares 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021(vesting conditions set out in NOM for General Meeting held on 7 May 2018) 400,000 Unlisted Options exercisable at $0.583 expiring 14 October 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation inbuy-back	Expiry of Unlisted Warrants

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3